| Skin Cancer |
1 |
1 |
| Melanoma |
0 |
0.99 |
| Vitiligo |
0 |
0.54 |
| Skin and Soft Tissue Infection |
0 |
0.49 |
| BRAF Inhibitor |
0 |
0.43 |
| Cancer |
0 |
0.43 |
| BRAF |
0 |
0.34 |
| Pruritus |
0 |
0.98 |
| Acne |
0 |
0.31 |
| Renal Cell Carcinoma |
0 |
0.28 |
| Nail |
0 |
0.27 |
| Targeted Cancer Therapy |
0 |
0.26 |
| Biologic Therapy |
0 |
0.25 |
| Advanced Cancer |
0 |
0.24 |
| Toxicology |
0 |
0.22 |
| Radiation Therapy |
0 |
0.2 |
| Palliative Care |
0 |
0.18 |
| Bullous Pemphigoid |
0 |
0.14 |
| Drug Reaction |
0 |
0.14 |
| Hair |
0 |
0.14 |
| Lymphocytes |
0 |
0.14 |
| Neoplasm |
0 |
0.14 |
| Onycholysis |
0 |
0.14 |
| Paronychia |
0 |
0.14 |
| T-Lymphocyte |
0 |
0.14 |
| Dermatitis |
0 |
0.1 |
| Ablation |
0 |
0.07 |
| Adverse Effects |
0 |
0.07 |
| Antifungal |
0 |
0.07 |
| Antigens |
0 |
0.07 |
| Continuing Medical Education |
0 |
0.07 |
| Corticosteroids |
0 |
0.07 |
| Cytokines |
0 |
0.07 |
| Drug Eruption |
0 |
0.07 |
| Eosinophilia |
0 |
0.07 |
| Erythema Multiforme |
0 |
0.07 |
| Erythroderma |
0 |
0.07 |
| Lichen Planus |
0 |
0.07 |
| Mucositis |
0 |
0.07 |
| Pain |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Steroids |
0 |
0.07 |
| Stevens-Johnson Syndrome |
0 |
0.95 |
| Toxic Epidermal Necrolysis |
0 |
0.07 |